These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24274772)

  • 1. Association of activated partial thromboplastin time and fibrinogen level in patients with type II diabetes mellitus.
    Sapkota B; Shrestha SK; Poudel S
    BMC Res Notes; 2013 Nov; 6():485. PubMed ID: 24274772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of coagulation profile with microvascular complications and glycemic control in type 2 diabetes mellitus - a study at a tertiary care center in Delhi.
    Agarwal C; Bansal K; Pujani M; Singh K; Chauhan V; Rana D; Lukhmana S
    Hematol Transfus Cell Ther; 2019; 41(1):31-36. PubMed ID: 30793102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shortened Activated Partial Thromboplastin Time and Increased Superoxide Dismutase Levels Are Associated with Type 2 Diabetes Mellitus.
    Fu G; Yan Y; Chen L; Zhang M; Ming L
    Ann Clin Lab Sci; 2018 Jul; 48(4):469-477. PubMed ID: 30143488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High risk of coagulopathy among Type-2 Diabetes Mellitus clients at a municipal hospital in Ghana.
    Ephraim RK; Awuku YA; Adu P; Ampomah LT; Adoba P; Panford S; Ninnoni JP; Agbodzakey H
    Ghana Med J; 2017 Sep; 51(3):101-107. PubMed ID: 29622820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values.
    Zhao Y; Zhang J; Zhang J; Wu J
    PLoS One; 2011 Jan; 6(1):e16470. PubMed ID: 21297995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of measurement of plasma fibrinogen level among patients with type- 2 diabetes mellitus.
    Abdul Razak MK; Sultan AA
    Diabetes Metab Syndr; 2019; 13(2):1151-1158. PubMed ID: 31336458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mean platelet volume and platelet counts in type 2 diabetes: mellitus on treatment and non-diabetic mellitus controls in Lagos, Nigeria.
    Akinsegun A; Akinola Olusola D; Sarah JO; Olajumoke O; Adewumi A; Majeed O; Anthonia O; Ebele U; Olaitan O; Olanrewaju A; Kingsley A
    Pan Afr Med J; 2014; 18():42. PubMed ID: 25368731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic indices for intra-hospital mortality in Nigerian diabetic NIDDM patients. Role of gender and hypertension.
    Kolawole BA; Ajayi AA
    J Diabetes Complications; 2000; 14(2):84-9. PubMed ID: 10959070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria.
    Yusuff KB; Obe O; Joseph BY
    Pharm World Sci; 2008 Dec; 30(6):876-83. PubMed ID: 18784982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Significance of Hemostatic Parameters in the Prediction for Type 2 Diabetes Mellitus and Diabetic Nephropathy.
    Pan L; Ye Y; Wo M; Bao D; Zhu F; Cheng M; Ni X; Fei X
    Dis Markers; 2018; 2018():5214376. PubMed ID: 29511389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes.
    Fanghänel G; Silva U; Sanchez-Reyes L; Sisson D; Sotres D; Torres EM
    Rev Invest Clin; 1998; 50(5):389-94. PubMed ID: 9949668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prothrombin time, activated partial thromboplastin time and platelet counts of type II diabetes mellitus: a comparative study.
    Ambelu YA; Shiferaw MB; Abebe M; Enawgaw B
    J Diabetes Metab Disord; 2018 Dec; 17(2):117-121. PubMed ID: 30918844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinogen Levels in Type 2 Diabetes Mellitus and it's Correlation with Microvascular Microvascular Complications.
    M RK; L H
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of lipid profile in type-2 obese diabetics and obese non-diabetic individuals. a hospital based study from Western Nepal.
    Yadav NK; Thanpari C; Shrewastwa MK; Mittal RK
    Kathmandu Univ Med J (KUMJ); 2012; 10(39):44-7. PubMed ID: 23434961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevalence of diabetes, antidiabetic treatment and chronic diabetic complications reported by general practitioners].
    Fabian W; Majkowska L; Stefański A; Moleda P
    Przegl Lek; 2005; 62(4):201-5. PubMed ID: 16229234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycaemic control improves fibrin network characteristics in type 2 diabetes - a purified fibrinogen model.
    Pieters M; Covic N; van der Westhuizen FH; Nagaswami C; Baras Y; Toit Loots D; Jerling JC; Elgar D; Edmondson KS; van Zyl DG; Rheeder P; Weisel JW
    Thromb Haemost; 2008 Apr; 99(4):691-700. PubMed ID: 18392327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variations and clinical significance of coagulation and fibrinolysis parameters in patients with diabetes mellitus.
    Hu J; Wei W; Din G; Yuan L; Liu Z
    J Tongji Med Univ; 1998; 18(4):233-5. PubMed ID: 10806853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-Diabetics with Hypovitaminosis D Have Higher Risk for Insulin Resistance.
    Nur-Eke R; Özen M; Çekin AH
    Clin Lab; 2019 May; 65(5):. PubMed ID: 31115227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study.
    Cathelineau G; de Champvallins M; Bouallouche A; Lesobre B
    Metabolism; 1997 Dec; 46(12 Suppl 1):31-4. PubMed ID: 9439556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.